Alexandre Deseabra

Biography

Mr. Alexandre DeSeabra is the President and Founder at BioFactura, Inc. Mr. DeSeabra brings over 15 years of experience in biotechnology to BioFactura. From bench-scale research to large-scale manufacturing, Mr. DeSeabra has worked with both microbial and mammalian systems producing a broad spectrum of biologics. Before founding BioFactura, Mr. DeSeabra managed several manufacturing groups at Human Genome Sciences, Inc. (HGS) overseeing technicians, engineers, and the production of five therapeutic proteins, one monoclonal antibody, and one gene therapy. Mr. DeSeabra joined the Process Development Department at HGS in 1997 where he optimized processes for the recovery and purification of Mirostipen™ (Myeloid Progenitor Inhibitory Factor). He also assisted in the start-up and commissioning of the company’s first small-scale cGMP production suite and the Pilot Production Facility. Prior to HGS, Mr. DeSeabra worked with an emerging vaccine company, North American Vaccine, Inc. (now owned by Baxter, Inc.). There, he supported development of several vaccines including the internationally–approved Neis-Vac C™. Additionally, he managed a monoclonal antibody production laboratory and participated in the startup and commissioning of a large-scale vaccine production facility. After facility validation, Mr. DeSeabra worked as a purification supervisor for the cGMP manufacture of the EMEA and FDA-approved pertussis vaccine, Certiva™. Mr. DeSeabra started his career in 1987 at the Laboratory of Cellular and Molecular Biology of the National Cancer Institute (NCI). During his four-years at NCI he researched PDGF- 2 (Platelet Derived Growth Factor), an important human chemokine. 

Research Interest

Cellular and Molecular Biology